Intraperitoneal chemotherapy for epithelial ovarian cancer

Obstetrical and Gynecological Survey

Volumn 61, Issue 8, 2006, Pages 529-534

  AlHayki, Maryam ^a,b   Hopkins, Laura ^a   Le, Tien ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ABSORPTION; FATIGUE; HEARING LOSS; HUMAN; METABOLIC DISORDER; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PAIN; PARESTHESIA; PERITONITIS; REVIEW; TINNITUS; VOMITING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFUSIONS, PARENTERAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746470369     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000228777.15365.32     Document Type: Review

References (41)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995;13:783-793.
3. DiSia PJ, Creasman WT. Clinical Gynecologic Oncology. St. Louis: Mosby-Year Book, Inc, 2002:289-350.
4. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Nat Cancer Inst Monogr 1975;42:101-104.
5. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-420.
6. Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log [relative risk]) as main objectives. Eur J Cancer Clin Oncol 1989;25:711-720.
7. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
8. Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002;29(suppl 1):3-8.
9. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.
10. Tingulstad S, Skjeldestad FE, Halvorsen TB, et al. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-891.
11. Gillette-Cloven N, Burger RA, Monk BJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 2001;193:626-632.
12. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006;100:27-32.
13. Babb AL, Johansen PJ, Strand MJ, et al. Bi-directional permeability of the human peritoneum to middle molecules. Proc Eur Dial Transplant Assoc 1973;10:247-262.
14. Maher JF. Peritoneal transport rates: mechanisms, limitations, and methods for augmentation. Kidney Int Suppl 1980;10:S117-120.
15. Hofstra LS, de Vries EG, Mulder NH, et al. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 2000;26:133-143.
16. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-851.
17. Markman M, Rowinsky E, Hakes T. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group Study. J Clin Oncol 1992;9:1485-1491.
18. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995;13:2961-2967.
19. Markman M, Berek JS, Blessing JA, et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992;45:3-8.
20. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer : influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-1805.
21. Markman M, Blessing JA, Major F, et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Gynecol Oncol 1993;50:191-195.
22. Braly PS, Berek JS, Blessing JA, et al. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial. Gynecol Oncol 1995;56:164-168.
23. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-2624.
24. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
25. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
26. Armstrong DK, Bundy B, Wenzel L, et al.; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
27. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006;1:CD005340.
28. Ozols RF, Bundy BN, Greer BE, et al.; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
29. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003;90:637-643.
30. Miyagi Y, Fujiwara K, Kigawa J, et al.; Sankai Gynecology Study Group (SGSG). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin - a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 2005;99:591-596.
31. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006;24:988-994.
32. Naumann RW, Alvarez RD, Partridge EE, et al. The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients. Gynecol Oncol 1993;50:291-293.
33. Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001;81:77-81.
34. Fujiwara K, Suzuki S, Ishikawa H, et al. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer 2005;15:426-431.
35. Ghosh K, Geller MA, Twiggs LB. Erosion of an intraperitoneal chemotherapy catheter resulting in an enterovaginal fistula. Gynecol Oncol 2000;77:327-329.
36. Bilsel Y, Balik E, Bugra D, et al. A case of protrusion of an intraperitoneal chemotherapy catheter through rectum. Int J Gynecol Cancer 2005;15:171-174.
37. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-180.
38. Junor EJ, Hole DJ, McNulty L, et al. Specialist gynecologists and survival outcome in ovarian cancer. A Scottish national study of 1966 patients. Br J Obstet Gynaecol 1999;106:1130-1136.
39. Olaitan A, Weeks J, Mocroft A, et al. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer 2001;85:1824-1830.
40. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-209.
41. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003;102:499-505.